Tuberculosis Diagnosis and Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Disease Type (Active TB, and Latent TB); Therapy (First-Line Therapy, and Second-Line Therapy); End Use (Clinics, Hospitals, Research Institutes and Academics, Reference Laboratories, and Others), and Geography
Tuberculosis (TB) is a chronic disease and has become a global disease. Manufacturers of TB drugs are concerned with developing medications that can shorten the duration of treatment and help overcome the challenges of drug-susceptible TB and drug-resistant TB. TB treatment is divided into two types, such as first-line treatment, second-line treatment, and drug-resistant treatment. Advanced technologies and the introduction of novel therapies are expected to improve the duration of treating TB. However, most TB cases with currently available medicines can require up to 6 months of treatment. However, despite existing drugs and ongoing TB treatment drugs innovations, there is a continuous need to improve patients' access to appropriate TB medicines, particularly in the areas of multidrug-resistant TB (MDR TB) and pediatric TB.
The "Global Tuberculosis Diagnosis and Treatment Market Analysis to 2028" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of the tuberculosis diagnosis and treatment market with detailed market segmentation by disease type, therapy, end use, and geography. The report provides key statistics on the market status of the leading tuberculosis diagnosis and treatment market players and offers key trends and opportunities in the market.
Based on disease type, the global tuberculosis diagnosis and treatment market is segmented into active tb, latent tb.
On the basis of therapy, the market is segmented into first-line therapy, second-line therapy.
On the basis of end use, the market is segmented into clinics, hospitals, research institutes and academics, reference laboratories, others.
MARKET DYNAMICS Drivers
Rise in the incidences of drug susceptible tuberculosis.
Advancements in testing kits technology.
Increase research and development towards drug developments
The Second line treatment drugs are highly priced compared to first line treatment with more side effects and high level toxicity is the major restraining factor for this market.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The tuberculosis diagnosis and treatment market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the tuberculosis diagnosis and treatment market in these regions.
IMPACT OF COVID-19 ON TUBERCULOSIS DIAGNOSIS AND TREATMENT MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
Get more information on this report :
The report covers key developments in the tuberculosis diagnosis and treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from tuberculosis diagnosis and treatment market are anticipated to lucrative growth opportunities in the future with the rising demand for tuberculosis diagnosis and treatment in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the tuberculosis diagnosis and treatment market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
St. Jude Medical (Abbott)
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
Get more information on this report :
The List of Companies
1. Abbott Laboratories Inc.
2. Akonni Biosystems, Inc.
3. Alere, Inc.
4. Becton Dickinson and Co.
5. Biochemical and Synthetic Products Pvt Ltd
6. Biomérieux SA
7. Cepheid Inc.
8. Eiken Chemical Co. Ltd.
10. F. Hoffmann-LA Roche AG
11. GlaxoSmithKline PLC
12. Hain Lifescience GmbH
14. Johnson & Johnson Services, Inc.
15. LabatecPharma SA
16. Lupin Pharmaceuticals Inc.
17. Novartis AG
18. Otsuka Pharmaceutical Co. Ltd.
19. PerkinElmer Inc.
20. Lupin Pharmaceuticals Inc